A detailed history of Principal Financial Group Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Principal Financial Group Inc holds 2,437,886 shares of BMY stock, worth $101 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
2,437,886
Previous 2,424,604 0.55%
Holding current value
$101 Million
Previous $124 Million 6.27%
% of portfolio
0.08%
Previous 0.08%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$47.98 - $54.4 $637,270 - $722,540
13,282 Added 0.55%
2,437,886 $132 Million
Q4 2023

Feb 07, 2024

SELL
$48.48 - $57.85 $15.1 Million - $18 Million
-310,855 Reduced 11.36%
2,424,604 $124 Million
Q3 2023

Nov 02, 2023

SELL
$57.89 - $64.73 $6.42 Million - $7.18 Million
-110,846 Reduced 3.89%
2,735,459 $159 Million
Q2 2023

Aug 07, 2023

SELL
$63.71 - $70.74 $26.6 Million - $29.5 Million
-417,523 Reduced 12.79%
2,846,305 $182 Million
Q1 2023

May 09, 2023

SELL
$65.71 - $74.53 $3.22 Million - $3.66 Million
-49,068 Reduced 1.48%
3,263,828 $226 Million
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $17.1 Million - $20.2 Million
249,290 Added 8.14%
3,312,896 $238 Million
Q3 2022

Nov 09, 2022

BUY
$0.13 - $76.84 $3,512 - $2.08 Million
27,016 Added 0.89%
3,063,606 $218 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $184,454 - $203,149
2,540 Added 0.08%
3,036,590 $234 Million
Q1 2022

May 09, 2022

BUY
$61.48 - $73.72 $5.72 Million - $6.86 Million
93,104 Added 3.17%
3,034,050 $222 Million
Q4 2021

Feb 09, 2022

SELL
$53.63 - $62.52 $14.6 Million - $17.1 Million
-273,099 Reduced 8.5%
2,940,946 $183 Million
Q3 2021

Nov 09, 2021

SELL
$59.17 - $69.31 $8.56 Million - $10 Million
-144,718 Reduced 4.31%
3,214,045 $190 Million
Q2 2021

Aug 10, 2021

SELL
$61.91 - $67.42 $5.57 Million - $6.07 Million
-89,982 Reduced 2.61%
3,358,763 $224 Million
Q1 2021

May 10, 2021

SELL
$59.34 - $66.74 $12.4 Million - $13.9 Million
-208,595 Reduced 5.7%
3,448,745 $218 Million
Q4 2020

Feb 23, 2021

SELL
$57.74 - $65.43 $59.3 Million - $67.2 Million
-1,027,596 Reduced 21.93%
3,657,340 $227 Million
Q4 2020

Feb 08, 2021

BUY
$57.74 - $65.43 $58.1 Million - $65.8 Million
1,006,280 Added 27.35%
4,684,936 $291 Million
Q3 2020

Nov 06, 2020

SELL
$57.43 - $63.64 $6.72 Million - $7.44 Million
-116,926 Reduced 3.08%
3,678,656 $222 Million
Q2 2020

Aug 05, 2020

BUY
$54.82 - $64.09 $7.08 Million - $8.28 Million
129,150 Added 3.52%
3,795,582 $223 Million
Q1 2020

May 12, 2020

SELL
$46.4 - $67.43 $2.41 Million - $3.51 Million
-52,041 Reduced 1.4%
3,666,432 $204 Million
Q4 2019

Feb 05, 2020

BUY
$49.21 - $64.19 $42.1 Million - $54.9 Million
855,286 Added 29.87%
3,718,473 $239 Million
Q3 2019

Nov 13, 2019

SELL
$42.77 - $50.71 $2.69 Million - $3.18 Million
-62,808 Reduced 2.15%
2,863,187 $145 Million
Q2 2019

Aug 12, 2019

BUY
$44.62 - $49.34 $6.34 Million - $7.01 Million
141,996 Added 5.1%
2,925,995 $133 Million
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $336,008 - $400,648
-7,447 Reduced 0.27%
2,783,999 $133 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $16.5 Million - $21.4 Million
-338,500 Reduced 10.81%
2,791,446 $145 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $400,734 - $451,997
7,261 Added 0.23%
3,129,946 $194 Million
Q2 2018

Aug 13, 2018

BUY
$50.53 - $62.98 $1.44 Million - $1.8 Million
28,551 Added 0.92%
3,122,685 $0
Q1 2018

May 14, 2018

BUY
$59.92 - $68.98 $13.5 Million - $15.6 Million
225,999 Added 7.88%
3,094,134 $196 Million
Q4 2017

Feb 13, 2018

BUY
$59.94 - $65.35 $15.8 Million - $17.2 Million
263,884 Added 10.13%
2,868,135 $176 Million
Q3 2017

Nov 02, 2017

BUY
$55.23 - $63.74 $144 Million - $166 Million
2,604,251
2,604,251 $166 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $88.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.